CDR111, an experimental MS therapy designed to eliminate harmful B-cells, reached an early development milestone.

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

The article, titled "Emerging roles of immune cell-derived neurotransmitters in immunity and disease," published on March 17, ...

Gilead Sciences (GILD) on Monday said it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...